Search filters

List of works by Sebastiano Buti

"Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?

scientific article

A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?

scientific article published on 01 March 2020

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

scientific article published on 27 February 2019

A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis

scientific article published on August 1, 2012

A new prognostic model for localized renal cell carcinoma

scientific article published on 21 May 2018

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

scientific article published on 01 August 2019

ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients

scientific article published on 7 July 2015

AR-V7 and prostate cancer: The watershed for treatment selection?

scientific article published on 18 December 2015

Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib

scientific article published on 28 July 2020

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

scientific article published on 21 February 2012

Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report

scientific article published on 27 May 2020

Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)

scientific article published on 01 August 2018

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

scientific article published on 14 December 2016

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

scientific article published on 04 February 2020

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

scientific article published on 09 April 2019

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

scientific article published on 05 February 2020

Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma

Axitinib dose titration: what's the limiting factor?

scientific article published on 18 October 2013

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

scientific article published on 01 July 2014

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

scientific article published on 01 October 2020

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

scientific article

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

scientific article published on 31 October 2020

Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

scientific article published on 15 July 2020

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population

scientific article published on 13 May 2019

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

scientific article published on 2 August 2017

Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma

scientific article published in January 2012

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

scientific article

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

scientific article published on 22 October 2020

Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile

scientific article published on 01 December 2008

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

scientific article published on 22 February 2019

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

scientific article published on 01 June 2018

Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy

scientific article published on 15 September 2020

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

scientific article published on 29 May 2017

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.

scientific article

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

scientific article published on 30 May 2020

Combination therapy in kidney cancer: the next revolution?

scientific article published on 22 October 2015

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

scientific article

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

scientific article published on 20 May 2020

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

scientific article published on 21 February 2019

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab

scientific article published on 23 December 2019

Does the Cetuximab Plus Paclitaxel Combination Deserve to Be Studied in a Phase III Trial? ⬇️

scientific article published on March 11, 2013

Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study

scientific article

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).

scientific article

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

scientific article published on 16 November 2020

Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review

scientific article published on 11 July 2019

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

scientific article published on March 2015

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

scientific article published on 07 January 2020

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

scientific article

Family history of cancer and DNA damage response genes: Two sides of the same coin?

scientific article published on 08 December 2018

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

scientific article published on 22 March 2018

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

scientific article published on 11 September 2017

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

scientific article published on 29 December 2016

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.

scientific article published on February 2017

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC

scientific article published on 19 March 2019

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

scientific article

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma

scientific article published on 01 January 2019

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

scientific article

Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature

scientific article published on 01 September 2018

Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature

scientific article published on 08 July 2019

Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.

scientific article published on October 2006

Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis

scientific article published on 19 January 2020

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

scientific article published on 01 February 2020

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma

scientific article published on 03 October 2011

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer

scientific article published on 17 June 2016

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.

scientific article

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.

scientific article published on March 2015

Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

scientific article published on 06 March 2017

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

scientific article published on 07 May 2018

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

scientific article published in July 2018

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

scientific article published on 03 November 2020

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

scientific article published on 01 June 2020

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.

scientific article

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

scientific article published on 19 July 2019

Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program

article

Non-clear-cell renal carcinoma therapy: handle with care

scientific article published on 02 March 2016

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review

scientific article published on 28 January 2016

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis

scientific article published on 7 August 2017

Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report

scientific article

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study

scientific article published on 13 December 2019

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

scientific article published on 01 March 2019

Patient performance status and cancer immunotherapy efficacy: a meta-analysis

scientific article published on 20 August 2018

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.

scientific article published on 24 April 2019

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

scientific article published on 26 May 2020

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.

scientific article

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

article

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.

scientific article published on 25 September 2009

Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma

scientific article published on 23 June 2020

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

scientific article

Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review

scientific article

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?

scientific article published on January 2015

Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review

scientific article published on 24 October 2019

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

scientific article published on 02 August 2014

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

scientific article published on 6 January 2015

Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series

scientific article published on 13 August 2018

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

scientific article published on 30 December 2019

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

article

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis

scientific article published on 01 November 2018

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

scientific article published on 23 March 2016

Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).

scientific article published on October 2007

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches"

scientific article published on 01 July 2019

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

article

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study

scientific article published on 10 October 2018

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

scientific article published on 23 July 2018

Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II tr

scientific article

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

article

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

scientific article published on 08 May 2019

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma

scientific article published on 18 July 2014

Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors

scientific article published on 4 December 2014

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

scientific article published on 02 November 2020

Systemic adjuvant therapies in renal cell carcinoma

scientific article published on 8 October 2012

Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies

scientific article published on 19 December 2019

The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.

scientific article

The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors

scientific article published on 12 May 2020

The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes

scientific article published on 01 June 2019

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

scientific article published on 29 November 2018

The effect of a treatment delay on outcome in metastatic renal cell carcinoma

scientific article published on 29 March 2019

The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade

scientific article published in November 2017

The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma

scientific article published on 08 December 2020

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

scientific article published on 01 August 2018

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?

scientific article published on 01 September 2019

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

scientific article published on 29 September 2019

Unlocking the secret of the obesity paradox in renal tumours

scientific article published on 20 December 2019

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey

scientific article published on 24 February 2012

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population

scientific article published on 01 July 2018

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

scientific article published on 31 August 2017

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

scientific article published on 13 September 2019

Very late recurrence of an apparently benign pheochromocytoma

scientific article published in October 2015

When a thymic carcinoma "becomes" a GIST.

scientific article

Paulina is supported by:

About Paulina

Help